Avalo Therapeutics, Inc. (AVTX)
- Previous Close
14.98 - Open
15.00 - Bid 15.19 x 100
- Ask 15.84 x 100
- Day's Range
14.69 - 16.23 - 52 Week Range
3.95 - 1,130.40 - Volume
78,100 - Avg. Volume
679,940 - Market Cap (intraday)
16.484M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-114.00 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.00
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
www.avalotx.comRecent News: AVTX
Performance Overview: AVTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVTX
Valuation Measures
Market Cap
15.49M
Enterprise Value
8.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.16
Price/Book (mrq)
2.12
Enterprise Value/Revenue
4.48
Enterprise Value/EBITDA
-0.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.91%
Return on Equity (ttm)
--
Revenue (ttm)
1.92M
Net Income Avi to Common (ttm)
-31.54M
Diluted EPS (ttm)
-114.00
Balance Sheet and Cash Flow
Total Cash (mrq)
7.42M
Total Debt/Equity (mrq)
26.05%
Levered Free Cash Flow (ttm)
-20.79M